Chronic Lymphocytic Leukemia: Global Clinical Trial Landscape (2024)

Explore Novotech CRO's analysis of Chronic Lymphocytic Leukemia (CLL) to learn about the latest research, innovative therapies, and emerging clinical trials shaping CLL care.

CLL, a slow-progressing leukemia primarily affecting older adults, is characterized by dysfunctional B lymphocytes. Early stages are often asymptomatic, but symptoms like painless lymph node enlargement and fatigue can develop as the disease advances. With an 87% five-year survival rate for adults 20 and older, early detection is key.

Globally, there are about 490,000 leukemia cases, with 121,000 being CLL. The highest incidence is in Europe and North America, particularly in the US, Germany, China, France, and Italy.

Current treatments include surgery, radiation, chemotherapy, and stem cell transplantation. Advancements in research are focused on targeted therapies like Bruton's tyrosine kinase (BTK) inhibitors and BCL2 inhibitors, as well as CAR T-cell therapy.

Since 2019, over 1,000 CLL trials have been conducted, with significant activity in North America, Asia-Pacific, and Europe. Key contributors include the US, China, Spain, and France.

Marketed drugs such as Imbruvica (ibrutinib) and Zytux (biosimilar rituximab), along with promising late-stage drugs like nemtabrutinib and U2, are showing effectiveness.

With ongoing research into new therapies and targets like RNA splicing dysregulation, the future of CLL treatment looks promising. Novotech, a global leader in clinical research, supports numerous oncology projects and has received industry accolades.

Download our report for a detailed look at current CLL research and treatment developments.